Biopharma PEG Supplies PEG Products Used For Infectious Disease Vaccines

As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development.

Recombinant protein vaccines accounted for the largest proportion of all pipeline in development, 22% (215), due to their good safety, stability and ease of manufacture. Nearly 100 recombinant vaccine candidates are currently in Phase I clinical development, currently the largest number of all types.

The success of COVID-19 mRNA vaccines has laid the foundation for the development of nucleic acid vaccines, including mRNA and DNA vaccines. These vaccines now account for the second largest portion of the overall pipeline, accounting for 18% (173). Due to the flexibility of this class of vaccines in developing vaccines against highly variable pathogens, many vaccine candidates are currently in development, including COVID-19 (95 candidates), influenza (24), and HIV (21).

Viral vector vaccines have also attracted attention in recent years because of their potential to induce strong and long-lasting immune responses, including adenoviruses, retroviruses, lentiviruses, and poxviruses. Currently, there are 133 candidate virus vector vaccines under development, and in particular, adenovirus vectors (82) have been widely used to develop vaccines for diseases such as Ebola, HIV, influenza and COVID-19.

Conjugate vaccines followed with 11%, with 109 vaccine candidates. Conjugate vaccines are typically developed against pathogens such as meningococcus, pneumococcus and Haemophilus influenzae. These vaccines are based on the covalent linkage of immunogenic protein carriers (primarily tetanus toxoids, diphtheria toxoids, or group B meningococcal outer membrane proteins) to capsular polysaccharides or peptides to enhance immunogenicity and stability.

The top three diseases for which vaccines are being developed are all caused by viruses: COVID-19 (246; 25%), influenza (104; 11%) and HIV (84; 9%). In addition to more than 50 vaccines that have received market approval or emergency use authorization for COVID-19, 64 vaccine candidates have entered phase 3 or submitted marketing applications, 47% of which are mRNA vaccines. In the current pipeline, there are at least 14 nasal vaccines in development.

The high variability of the HIV viral genome and high levels of glycosylation of the HIV envelope glycoprotein (gp) often induce immune evasion, which has hindered the development of HIV vaccines. Currently, the hope is to stimulate the production of broadly neutralizing antibodies by targeting conserved regions of envelope proteins that vary little between HIV strains, such as gp160, gp41, and gp120. Novel vaccines such as viral vectors and mRNAs offer promise for the development of HIV vaccines, with two mRNA vaccines capable of inducing neutralizing antibody production currently in Phase I trials (NCT05001373).

As a professional PEG derivatives supplier, Biopharma PEG is committed to providing following PEG products as ingredients used in COVID-19 vaccines.

mPEG-N,N-Ditetradecylacetamide (ALC-0159) CAS No. 1849616-42-7
mPEG-DMG CAS NO. 160743-62-4
mPEG-CH2CH2CH2-NH2
mPEG-OH CAS NO.: 9004-74-4
mPEG-CM (mPEG-AA)
mPEG-DSPE CAS NO.: 147867-65-0
mPEG-DPPE CAS NO.: 205494-72-0

Biopharma PEG Scientific Inc.
Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA
TEL: 1-857-366-6766
Fax: 617-206-9595
Email: sales@biochempeg.com
Website: https://www.biochempeg.com/

Biopharma PEG Scientific Inc. is a biotechnology-oriented company in Watertown, Massachusetts. We are dedicated to manufacturing and supplying high purity monodispersed and polydispersed polyethylene glycol (PEG) derivatives and PEG raw material, PEGylation services, and custom PEG derivative synthesis to clients worldwide. We continuously expand the capability to provide large-scale manufacture of high purity PEG derivatives with an extensive variety of functional groups, in both non-GMP and GMP grade. These PEG linkers have been widely used in bioconjugation, antibody-drug conjugates (ADCs) therapeutic, click chemistry, 3d bioprinting, drug delivery and diagnostics field, etc.

This release was published on openPR.